I-MAB
-
Ticker
IMAB
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Shanghai, China
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in immuno-oncology. The Company’s mission is to bring transformational medicines to patients around the world through innovation. I-Mab’s innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates
…More is driven by the Company’s Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hong Kong and Maryland, United States.
I-MAB
Most Recent Responsibility Report
MOST RECENT
2021 Environmental, Social & Governance Report
Report Locked. I-MAB has reached its limit for free report views.
Our service enables potential investors to review the most recent and archived I-MAB Sustainability Report, I-MAB Corporate Social Responsibility Report, I-MAB CSR Report, I-MAB Corporate Responsibility, I-MAB CR Report, I-MAB Citizenship Report, I-MAB ESG Report, and I-MAB Environmental Report online.